IntrinsicIntrinsic
← All summaries

Generation Bio Co.

GBIO
Financials & Chart →

Business Summary

Generation Bio Co. is a biotechnology company focused on developing redosable therapeutics for T cell-driven autoimmune diseases. The company's core business model involves leveraging its cell-targeted lipid nanoparticle (ctLNP) system to selectively deliver small interfering RNA (siRNA) to T cells, aiming to reprogram them in vivo to reduce or eliminate autoreactive T cells . This approach is designed to precisely inhibit or silence disease-driving genes in autoimmunity, targeting proteins that are undruggable or poorly drugged by conventional modalities . The company generates revenue primarily through collaboration agreements, such as its ongoing partnership with ModernaTX, Inc. .

The company's technology centers on its proprietary ctLNP delivery system, which incorporates "stealth" technology to prevent interaction with serum-binding proteins, reducing liver and spleen clearance to less than 1% of the administered systemic dose in both mice and non-human primates . This allows for highly efficient, redosable, and selective delivery to target cells. The ctLNP system is modular and compatible with various nucleic acid payloads, including siRNA, mRNA, and closed-ended DNA (ceDNA) . The siRNA therapeutics utilize the RNA interference pathway to potently and precisely regulate protein expression in T cells. The company also has developed immune-quiet DNA (iqDNA), a variant of ceDNA, to enable long-lasting high levels of gene expression from non-integrating episomes while avoiding innate immune sensors .

For the fiscal year ended December 31, 2024, Generation Bio Co. reported a net loss of $131.7 million . This compares to net losses of $126.6 million for the year ended December 31, 2023 , and $136.6 million for the year ended December 31, 2022 . As of December 31, 2024, the company had an accumulated deficit of $703.0 million . The company has not generated revenue from product sales to date .

A significant operational development during the reported period is the ongoing collaboration with ModernaTX, Inc., initiated in March 2023 . This collaboration focuses on developing treatments for certain diseases by targeting delivery of nucleic acids to liver cells and certain cells outside of the liver. Under this agreement, Moderna made an upfront payment of $40 million and $7.5 million in prepaid research funding . Generation Bio is eligible to receive up to an aggregate of $1.8 billion in milestone payments upon the achievement of specified development, regulatory, commercial, and sales milestone events, research term extensions fees and exclusivity extension fees . The company also entered into a Share Purchase Agreement with Moderna, issuing and selling 5,859,375 shares of common stock to Moderna at a price of $6.14 per share, for an aggregate purchase price of $36.0 million . Additionally, the company notified its landlord of the termination of the Seyon Lease on January 31, 2024, due to alleged breach of obligations, and is currently involved in litigation regarding this lease, with the court ordering monthly payments equal to rent and other charges .

Business Outlook

Generation Bio Co. expects to announce the target and indication of its lead T cell-selective LNP-siRNA program for autoimmune disease by mid-year 2025 . The company plans to submit its first investigational new drug (IND) application for this lead program in the second half of 2026 . The selection of the lead program is based on choosing protein targets linked to disease biology that require genetically precise engagement by siRNA and selective delivery by ctLNP .

The company's growth strategy includes developing a broad and diversified pipeline of T cell-driven autoimmune programs, guided by its target selection strategy and technology capabilities . This involves expanding its portfolio of indications for each target and identifying new high-value, undruggable, or poorly drugged therapeutic targets to address unmet needs in T cell-driven autoimmune diseases . The company also aims to expand and protect its intellectual property, including its broad patent estate covering fundamental LNP technology and methods to avoid or reduce immune response .

Operationally, the company plans to continue building its organizational capabilities, including expertise in key therapeutic areas and functions, viewing these as a strategic advantage . The company does not currently own or operate manufacturing facilities and expects to rely on third-party manufacturers for preclinical, clinical, and commercial quantities of its materials . The company believes that its existing cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into the second half of 2027 .

The company's capital allocation plans include continued investment in research and development programs, expanding its proprietary technologies, and advancing product candidates into preclinical and clinical development . It also includes obtaining, expanding, maintaining, defending, and enforcing its intellectual property portfolio, and seeking marketing approvals for product candidates . The company expects to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution if it obtains marketing approval for any product candidates .

Risk Factors

Generation Bio Co. faces substantial risks, including the inherent uncertainty of early-stage drug development, as it has not identified any product candidates for IND-enabling studies or clinical development, making it many years before potential commercialization, if ever . The company will require substantial additional funding, and an inability to raise capital when needed could force delays, reductions, or elimination of product development programs or commercialization efforts . There is a high risk of failure for product candidates in clinical trials, and delays in commencement, enrollment, or completion of trials, or failure to demonstrate purity, potency, and safety, could prevent timely commercialization . Nucleic acid therapies are an emerging area with scientific and other risks, and the company's limited experience in nucleic acid therapies and manufacturing, and no prior experience in clinical development, may limit success or delay efforts . Undesirable side effects or unexpected adverse properties of product candidates could delay or prevent regulatory approval, limit commercial potential, or result in negative consequences post-approval . The outcome of preclinical studies may not be predictive of later preclinical or clinical trial results . The manufacture of nucleic acid therapies is complex and difficult, posing scientific and technical risks that could lead to manufacturing problems and delays . The company relies on third parties for manufacturing, research, and preclinical and clinical testing, and their unsatisfactory performance could materially harm the business . Failure to obtain and maintain patent protection or if the scope is not sufficiently broad, could allow competitors to develop similar products . The company may continue to incur costs related to the Seyon Lease litigation, potentially impacting its financial condition . Changes in patent laws or their interpretation, or challenges to inventorship or ownership of intellectual property, could diminish the value of patents and impair the company's ability to protect its technology .

Management Priorities

Management emphasizes a strategy to change what is possible for people with T cell-driven autoimmune diseases by developing redosable therapeutics that reprogram T cells in vivo . The company's strategic priorities include selecting and advancing its lead T cell-selective LNP-siRNA program, with an expected target and indication announcement by mid-year 2025 and an IND application submission in the second half of 2026 . Other priorities involve developing a broad and diversified pipeline of T cell-driven autoimmune programs, expanding and protecting intellectual property, executing on existing and pursuing additional synergistic collaborations, and building organizational capabilities . Management believes that existing cash, cash equivalents, and marketable securities will fund operating expenses and capital expenditure requirements into the second half of 2027 .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Our strategy
  3. [3] Item 1, Business — Risks related to our financial position and need for additional capital
  4. [4] Item 1, Business — Our redosable, highly selective cell-targeted LNP delivery system
  5. [5] Item 1, Business — Our redosable, highly selective cell-targeted LNP delivery system
  6. [6] Item 1, Business — Other technologies iqDNA
  7. [7] Item 1A, Risk Factors — Risks related to our financial position and need for additional capital
  8. [8] Item 1A, Risk Factors — Risks related to our financial position and need for additional capital
  9. [9] Item 1A, Risk Factors — Risks related to our financial position and need for additional capital
  10. [10] Item 1A, Risk Factors — Risks related to our financial position and need for additional capital
  11. [11] Item 1A, Risk Factors — Risks related to our financial position and need for additional capital
  12. [12] Item 1, Business — Collaboration and license agreement with Moderna
  13. [13] Item 1, Business — Collaboration and license agreement with Moderna
  14. [14] Item 1, Business — Collaboration and license agreement with Moderna
  15. [15] Item 1, Business — Collaboration and license agreement with Moderna
  16. [16] Item 1A, Risk Factors — We may continue to incur costs related to the Seyon Lease.
  17. [17] Item 1, Business — Next steps
  18. [18] Item 1, Business — Next steps
  19. [19] Item 1, Business — Our strategy
  20. [20] Item 1, Business — Our strategy
  21. [21] Item 1, Business — Our strategy
  22. [22] Item 1, Business — Our strategy
  23. [23] Item 1, Business — Our strategy
  24. [24] Item 1, Business — Manufacturing
  25. [25] Item 1A, Risk Factors — We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  26. [26] Item 1A, Risk Factors — We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  27. [27] Item 1A, Risk Factors — We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  28. [28] Item 1A, Risk Factors — We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  29. [29] Item 1A, Risk Factors — We are very early in our development efforts. We have not identified any product candidates for Investigational New Drug, or IND, -enabling studies or clinical development, and as a result it will be years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.
  30. [30] Item 1A, Risk Factors — We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  31. [31] Item 1A, Risk Factors — We may encounter substantial delays in commencement, enrollment or completion of our clinical trials or we may fail to demonstrate purity, potency and safety to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all.
  32. [32] Item 1A, Risk Factors — Nucleic acid therapies are an emerging area of drug development that poses many scientific and other risks. We have only limited prior experience in nucleic acid therapies and manufacturing and no prior experience in clinical development of nucleic acid therapies. Our lack of experience for our nucleic acid therapies may limit our ability to be successful or may delay our development efforts.
  33. [33] Item 1A, Risk Factors — If any product candidates we may develop cause undesirable side effects or have other unexpected adverse properties, such side effects or properties could delay or prevent regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.
  34. [34] Item 1A, Risk Factors — The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials.
  35. [35] Item 1A, Risk Factors — The manufacture of any product candidates we may develop will be subject to a number of scientific and technical risks, some of which are common to the manufacture of drugs and biologics and others of which may be unique to the manufacture of any product candidate we may develop. We could experience manufacturing problems that result in delays in our development or commercialization programs.
  36. [36] Item 1A, Risk Factors — We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.
  37. [37] Item 1A, Risk Factors — If we or our licensors are unable to obtain, maintain and defend patent and other intellectual property protection for our product candidates and technology, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully develop and commercialize any product candidates we may develop or our technology may be adversely affected due to such competition.
  38. [38] Item 1A, Risk Factors — We may continue to incur costs related to the Seyon Lease.
  39. [39] Item 1A, Risk Factors — Changes in patent law in the United States or worldwide could diminish the value of patents in general, thereby impairing our ability to protect any product candidates we may develop and our technology.
  40. [40] Item 1, Business — Our strategy
  41. [41] Item 1, Business — Our strategy
  42. [42] Item 1, Business — Our strategy
  43. [43] Item 1, Business — Our strategy
  44. [44] Item 1A, Risk Factors — We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.

Analysis on 5/21/2026